Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults. - Wikidata - awgldk - TriplyDB

Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.

Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.

http://www.wikidata.org/entity/Q38079075

about

Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008)Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia.Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional study From the Children's Oncology Group: Evidence-Based Recommendations for PEG-Asparaginase Nurse Monitoring, Hypersensitivity Reaction Management, and Patient/Family Education.Reactions related to asparaginase infusion in a 10-year retrospective cohort.Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.

P2860

Q26784116-642A0D12-89DD-4B9B-94A0-5C64FBDD0D58 Q27026952-D75D66A4-4616-4730-8348-A54B86B58F6E Q35803355-FF962B43-C27D-4604-A661-54F7F5D6578A Q37709190-7B266675-3CE4-47EB-820A-C484BD28BE2A Q38880102-D0CA6A7E-4767-4580-87A9-F8F919FEB148 Q38933372-13D5F6B6-531F-410B-B3E1-E960D7A2CE9F Q38994917-B924ED67-08D7-446F-8BC4-7C2778B110BE Q41491082-FA8A4A90-17A7-4316-8364-653572861597 Q45162637-BF480538-EC93-431B-AA5B-1BD731BA49D9 Q47133515-5BEF3AD9-8C3B-42BC-A84A-21D62709E202 Q50868882-D4407F71-25CA-475C-AF1F-31A4439F13E5

P2860

Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.

http://www.wikidata.org/entity/Q38079075

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.

@en

type

label

Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.

@en

prefLabel

Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.

@en

P1433

Q38079075-4FCF6930-E779-4FED-82ED-11F8D0658657

P1476

Q38079075-5079C43D-E474-427E-B050-B7490E9C5133

P2093

Q38079075-29295D17-AE71-4C3B-86F6-91591DFCB838

Q38079075-7A4F061B-CC7A-4B12-A0FE-08B663CE821B

Q38079075-9BBD4267-F120-4360-8D41-A8484FA022E0

P2860

Q38079075-153CE238-81E4-4605-A1DF-0F91BF741368

Q38079075-157CF5EA-721E-4AB6-B89A-D3E9CDB7B5EE

Q38079075-21BECC90-5F4B-4115-ABF4-CA61A37A3430

Q38079075-3BCED879-5432-449A-96CF-141D89C4EE21

Q38079075-3F1149DA-FEAD-4D07-8972-C774AF45014A

Q38079075-3FDDC609-AB7A-4EC5-A2CE-0FE37DCA2CA9

Q38079075-469993D7-BAF9-4130-B8E1-465D94B14BDC

Q38079075-48B1CB5A-E006-4A89-AEE9-E97E728A9A5E

Q38079075-4B303BB8-FC58-4C5D-8D0D-2B2F3C0B8642

Q38079075-6245ABBB-88E7-47F7-ACCB-ECE8CA96AEED

P304

Q38079075-BF3EA5FA-84C0-4B86-8724-A118200FD3CB

P31

Q38079075-91E372ED-3C84-4004-9217-94A7A720BF2A

P356

Q38079075-4E01D83E-EEC7-4E8B-8162-6F02B7E835B5

P433

Q38079075-142CA3DF-E229-40CD-A121-DB9F4F511D2B

P478

Q38079075-75770E66-F28C-493D-B2FE-E1A44AC872AB

P577

Q38079075-47E6C431-E299-4FE5-B9D8-DA4DEC39EEB2

P698

Q38079075-D7ACF565-0FDA-4FAA-AAD4-27220ECBC352

P921

Q38079075-4722EFDC-1171-474C-AFF2-B619DACF588E

P356

1043454212471728

P1433

Journal of Pediatric Oncology Nursing

P1476

Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.

@en

P2093

Mary L Browning

http://www.w3.org/2001/XMLSchema#string

Sara E Shinnick

http://www.w3.org/2001/XMLSchema#string

Susannah E Koontz

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils

Pegaspargase: a review of clinical studies

Use of ?-asparaginase in childhood ALL

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.

Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.

Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity.

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase

Biology, risk stratification, and therapy of pediatric acute leukemias: an update.

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

P304

63-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1043454212471728

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23380527

http://www.w3.org/2001/XMLSchema#string

P921